Cargando…

Myocardial Regeneration via Progenitor Cell-Derived Exosomes

In the past 20 years, a variety of cell products has been evaluated in terms of their capacity to treat patients with acute myocardial infarction and chronic heart failure. Despite initial enthusiasm, therapeutic efficacy has overall been disappointing, and clinical application is costly and complex...

Descripción completa

Detalles Bibliográficos
Autores principales: Maring, Janita A., Beez, Christien M., Falk, Volkmar, Seifert, Martina, Stamm, Christof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733225/
https://www.ncbi.nlm.nih.gov/pubmed/29333167
http://dx.doi.org/10.1155/2017/7849851
_version_ 1783286866905137152
author Maring, Janita A.
Beez, Christien M.
Falk, Volkmar
Seifert, Martina
Stamm, Christof
author_facet Maring, Janita A.
Beez, Christien M.
Falk, Volkmar
Seifert, Martina
Stamm, Christof
author_sort Maring, Janita A.
collection PubMed
description In the past 20 years, a variety of cell products has been evaluated in terms of their capacity to treat patients with acute myocardial infarction and chronic heart failure. Despite initial enthusiasm, therapeutic efficacy has overall been disappointing, and clinical application is costly and complex. Recently, a subset of small extracellular vesicles (EVs), commonly referred to as “exosomes,” was shown to confer cardioprotective and regenerative signals at a magnitude similar to that of their donor cells. The conceptual advantage is that they may be produced in industrial quantities and stored at the point-of-care for off-the-shelf application, ideally without eliciting a relevant recipient immune response or other adverse effects associated with viable cells. The body of evidence on beneficial exosome-mediated effects in animal models of heart diseases is rapidly growing. However, there is significant heterogeneity in terms of exosome source cells, isolation process, therapeutic dosage, and delivery mode. This review summarizes the current state of research on exosomes as experimental therapy of heart diseases and seeks to identify roadblocks that need to be overcome prior to clinical application.
format Online
Article
Text
id pubmed-5733225
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-57332252018-01-14 Myocardial Regeneration via Progenitor Cell-Derived Exosomes Maring, Janita A. Beez, Christien M. Falk, Volkmar Seifert, Martina Stamm, Christof Stem Cells Int Review Article In the past 20 years, a variety of cell products has been evaluated in terms of their capacity to treat patients with acute myocardial infarction and chronic heart failure. Despite initial enthusiasm, therapeutic efficacy has overall been disappointing, and clinical application is costly and complex. Recently, a subset of small extracellular vesicles (EVs), commonly referred to as “exosomes,” was shown to confer cardioprotective and regenerative signals at a magnitude similar to that of their donor cells. The conceptual advantage is that they may be produced in industrial quantities and stored at the point-of-care for off-the-shelf application, ideally without eliciting a relevant recipient immune response or other adverse effects associated with viable cells. The body of evidence on beneficial exosome-mediated effects in animal models of heart diseases is rapidly growing. However, there is significant heterogeneity in terms of exosome source cells, isolation process, therapeutic dosage, and delivery mode. This review summarizes the current state of research on exosomes as experimental therapy of heart diseases and seeks to identify roadblocks that need to be overcome prior to clinical application. Hindawi 2017 2017-11-23 /pmc/articles/PMC5733225/ /pubmed/29333167 http://dx.doi.org/10.1155/2017/7849851 Text en Copyright © 2017 Janita A. Maring et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Maring, Janita A.
Beez, Christien M.
Falk, Volkmar
Seifert, Martina
Stamm, Christof
Myocardial Regeneration via Progenitor Cell-Derived Exosomes
title Myocardial Regeneration via Progenitor Cell-Derived Exosomes
title_full Myocardial Regeneration via Progenitor Cell-Derived Exosomes
title_fullStr Myocardial Regeneration via Progenitor Cell-Derived Exosomes
title_full_unstemmed Myocardial Regeneration via Progenitor Cell-Derived Exosomes
title_short Myocardial Regeneration via Progenitor Cell-Derived Exosomes
title_sort myocardial regeneration via progenitor cell-derived exosomes
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733225/
https://www.ncbi.nlm.nih.gov/pubmed/29333167
http://dx.doi.org/10.1155/2017/7849851
work_keys_str_mv AT maringjanitaa myocardialregenerationviaprogenitorcellderivedexosomes
AT beezchristienm myocardialregenerationviaprogenitorcellderivedexosomes
AT falkvolkmar myocardialregenerationviaprogenitorcellderivedexosomes
AT seifertmartina myocardialregenerationviaprogenitorcellderivedexosomes
AT stammchristof myocardialregenerationviaprogenitorcellderivedexosomes